安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Capstan Therapeutics
Capstan Therapeutics Home; Company; Pipeline; Science Platform; News Publications; Company; Science Platform; Pipeline; Culture Careers
- P Hours after R N S N t e N 60 N t e N T o c t e A Novel Product . . .
Capstan’s proprietary lipid nanoparticle is a non-viral dose-tunable system designed for increased tolerability and biodegradability to allow for repeat in vivo dosing CPTX2309 IS MADE UP OF THREE COMPONENTS: 1 LNP DELIVERY VEHICLE 2 CD8 TARGETING BINDERS 3 ENHANCED ANTI-CD19 CAR mRNA
- Capstan Therapeutics Presents Preclinical Data on Lead In Vivo CAR-T . . .
Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders
- Capstan Therapeutics Launches with $165 Million to Deliver on the . . .
Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need The core technology comprises targeted Lipid Nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body
- Capstan Therapeutics Announces $175M Oversubscribed Series B Financing . . .
SAN DIEGO, March 20, 2024 – Capstan Therapeutics, Inc (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced the successful closing of a $175M oversubscribed Series B financing
- Company - Capstan Therapeutics
We are a diverse team of experts integrating advancements in CAR-T therapy, mRNA, and LNPs, with rigorous focus to engineer transformative medicines
- Capstan Therapeutics to Present Preclinical Data on Lead In Vivo . . .
Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders
- Capstan Therapeutics to Participate in Jefferies Global Healthcare . . .
SAN DIEGO, May 28, 2025 – Capstan Therapeutics, Inc (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced that Capstan management will participate in the upcoming Jefferies Global Healthcare Conference 2025, being held
|
|
|